Yanshan Huang
Overview
Explore the profile of Yanshan Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu Y, Li Y, Cui R, Yan Y, Li F, Chen Y, et al.
Signal Transduct Target Ther
. 2025 Mar;
10(1):85.
PMID: 40069155
Large granular lymphocytic leukemia (LGLL) is characterized by the clonal proliferation of cytotoxic T lymphocytes or NK cells. Standard first-line immunosuppressive treatments have limitations, achieving complete remission (CR) rates of...
2.
Li Y, Cui R, Yu Y, Huang Y, Yan Y, Sun J, et al.
Oncologist
. 2025 Mar;
30(3).
PMID: 40063609
NK-large granular lymphocytic leukemia (NK-LGLL) is a rare chronic lymphoproliferative disorder and displays heterogeneity that remains insufficiently defined. CD56 plays a pivotal role in NK-cell maturation linked to cytotoxicity. However,...
3.
Yan Y, Huang Y, Yu Y, Duan Z, Li Y, Lyu R, et al.
Ann Hematol
. 2025 Feb;
PMID: 39998672
Recent advances in measurable residual disease (MRD) technology have significantly enhanced predictive accuracy for outcomes in various hematologic malignancies, serving as a crucial surrogate endpoint. However, in mantle cell lymphoma...
4.
Lv Z, He X, Li Z, Yuan Y, Zhou X, Tu C, et al.
Front Public Health
. 2025 Jan;
12:1523839.
PMID: 39877908
Objective: This study aimed to uncover the patterns of Human papillomavirus (HPV) infection outcomes in women and assess the risk factors that may affect these outcomes. Methods: A retrospective study...
5.
Deng L, Huang Y, Zhao F, Chen P, Huang X
Physiol Rep
. 2024 Nov;
12(21):e70126.
PMID: 39532808
FAM20C, a member of the family with sequence similarity 20, is involved in many physiological functions. Obesity, characterized by excessive accumulation of adipose tissue, has attracted more and more attention...
6.
Cui R, Yu Y, Li Y, Huang Y, Sun J, Yan Y, et al.
Br J Haematol
. 2024 Oct;
205(6):2506-2509.
PMID: 39419490
No abstract available.
7.
Yan Y, Yu Y, Xiong W, Wang J, Yao Y, Jia Y, et al.
Clin Cancer Res
. 2024 Oct;
30(23):5483-5493.
PMID: 39373694
Purpose: This study aims to explore the incidence and clinical features of MYD88 and CXCR4 mutations in patients with Waldenström macroglobulinemia (WM) and determine the optimal method for routine clinical...
8.
Shao Y, Chen Y, Zhu M, Liu Y, Fang C, Wang M, et al.
Diabetes Metab Syndr Obes
. 2024 Apr;
17:1563-1573.
PMID: 38601038
Introduction: Diabetes and obesity are momentous risk factors threatening people's lives and health. Currently available incretin analogue glucagon-like peptide 1 (GLP-1) possesses huge hypoglycemic effect with the unsatisfactory effect of...
9.
Ma Z, Zhou Z, Duan W, Yao G, Sheng S, Zong S, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(5):82.
PMID: 38554200
Background: Claudin 18.2 (CLDN18.2) is a highly anticipated target for solid tumor therapy, especially in advanced gastric carcinoma and pancreatic carcinoma. The T cell engager targeting CLDN18.2 represents a compelling...
10.
Fan W, Chen Y, Zhou Z, Duan W, Yang C, Sheng S, et al.
Int Immunopharmacol
. 2024 Feb;
130:111698.
PMID: 38377856
Immunosuppressive pathways in the tumor microenvironment (TME) are inextricably linked to tumor progression. Mono-therapeutics of immune checkpoint inhibitors (ICIs, e.g. antibodies against programmed cell death protein-1/programmed cell death ligand-1, PD-1/PD-L1)...